MiniMed (MMED): Nine Analysts Raised Targets, But Cash Flow Still Has a Catch
MiniMed Group (MMED) reported Q1 2027 revenue of $843M, up 16.6%, and raised full-year guidance. Analysts raised targets, citing pipeline progress and strong product momentum. However, adjusted EBITDA margin was 9.9%, and free cash flow was negative $90M due to separation costs and other expenses.
How this was made
The 30-second read
Why it matters
No new corporate event; the piece is a summary of existing data with analyst commentary.
Market read
Provides a brief update for traders already aware of the earnings; limited new trading impetus.
What to watch
Long‑term separation costs and the pace of exiting Medtronic service agreements.
Background
The article recaps MiniMed's Q1 earnings released weeks earlier and lists analyst target raises.
Ticker impact
MMED reported Q1 FY2027 results with 16.6% sales growth and negative $90M free cash flow after separation costs.
Limited upside unless cash flow improves; potential modest rally.
Upgrades are reactionary, not new fundamentals; cash burn may curb price gains.
Market effects
Shows medtech growth potential but highlights cash‑flow risk for similar spin‑offs.
US medtech stocks may see mixed reactions as investors weigh growth versus cash burn.
Limited; primarily affects niche diabetes device segment.
Counterpoint
The persistent cash burn and unresolved transition agreements could pressure the stock lower.
Key entities
- CompanyMiniMed Group, Inc.
Diabetes and medtech device maker.
